These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 35543701)

  • 1. Pharmacogenomic Study of Statin-Associated Muscle Symptoms in the ODYSSEY OUTCOMES Trial.
    Murphy WA; Lin N; Damask A; Schwartz GG; Steg PG; Szarek M; Banerjee P; Fazio S; Manvelian G; Pordy R; Shuldiner AR; Paulding C
    Circ Genom Precis Med; 2022 Jun; 15(3):e003503. PubMed ID: 35543701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative effects of high-dose atorvastatin versus rosuvastatin on lipid parameters, oxidized low-density lipoprotein, and proprotein convertase subtilisin kexin 9 in acute coronary syndrome.
    Altunkeser BB; Tuncez A; Ozturk B; Tezcan H; Ates MS; Yilmaz C; Yalcin MU; Aygul N; Demir K
    Coron Artery Dis; 2019 Jun; 30(4):285-290. PubMed ID: 30741744
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial.
    Schwartz GG; Bessac L; Berdan LG; Bhatt DL; Bittner V; Diaz R; Goodman SG; Hanotin C; Harrington RA; Jukema JW; Mahaffey KW; Moryusef A; Pordy R; Roe MT; Rorick T; Sasiela WJ; Shirodaria C; Szarek M; Tamby JF; Tricoci P; White H; Zeiher A; Steg PG
    Am Heart J; 2014 Nov; 168(5):682-9. PubMed ID: 25440796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of alirocumab in patients with hypercholesterolemia not adequately controlled with non-statin lipid-lowering therapy or the lowest strength of statin: ODYSSEY NIPPON study design and rationale.
    Teramoto T; Kondo A; Kiyosue A; Harada-Shiba M; Ishigaki Y; Tobita K; Kawabata Y; Ozaki A; Baccara-Dinet MT; Sata M
    Lipids Health Dis; 2017 Jun; 16(1):121. PubMed ID: 28623954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of alirocumab as add-on therapy in high-cardiovascular-risk patients with hypercholesterolemia not adequately controlled with atorvastatin (20 or 40 mg) or rosuvastatin (10 or 20 mg): design and rationale of the ODYSSEY OPTIONS Studies.
    Robinson JG; Colhoun HM; Bays HE; Jones PH; Du Y; Hanotin C; Donahue S
    Clin Cardiol; 2014 Oct; 37(10):597-604. PubMed ID: 25269777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A common missense variant of LILRB5 is associated with statin intolerance and myalgia.
    K Siddiqui M; Maroteau C; Veluchamy A; Tornio A; Tavendale R; Carr F; Abelega NU; Carr D; Bloch K; Hallberg P; Yue QY; Pearson ER; Colhoun HM; Morris AD; Dow E; George J; Pirmohamed M; Ridker PM; Doney ASF; Alfirevic A; Wadelius M; Maitland-van der Zee AH; Chasman DI; Palmer CNA;
    Eur Heart J; 2017 Dec; 38(48):3569-3575. PubMed ID: 29020356
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of SLCO1B1 c.521T>C (rs4149056) with discontinuation of atorvastatin due to statin-associated muscle symptoms.
    Linskey DW; English JD; Perry DA; Ochs-Balcom HM; Ma C; Isackson PJ; Vladutiu GD; Luzum JA
    Pharmacogenet Genomics; 2020 Dec; 30(9):208-211. PubMed ID: 32453264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patients With High Genome-Wide Polygenic Risk Scores for Coronary Artery Disease May Receive Greater Clinical Benefit From Alirocumab Treatment in the ODYSSEY OUTCOMES Trial.
    Damask A; Steg PG; Schwartz GG; Szarek M; Hagström E; Badimon L; Chapman MJ; Boileau C; Tsimikas S; Ginsberg HN; Banerjee P; Manvelian G; Pordy R; Hess S; Overton JD; Lotta LA; Yancopoulos GD; Abecasis GR; Baras A; Paulding C;
    Circulation; 2020 Feb; 141(8):624-636. PubMed ID: 31707832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of alirocumab on coronary atheroma volume in Japanese patients with acute coronary syndromes and hypercholesterolemia not adequately controlled with statins: ODYSSEY J-IVUS rationale and design.
    Ako J; Hibi K; Kozuma K; Miyauchi K; Morino Y; Shinke T; Tsujita K; Uno K; Kawabata Y; Hiro T
    J Cardiol; 2018 Jun; 71(6):583-589. PubMed ID: 29606415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intensity of statin treatment after acute coronary syndrome, residual risk, and its modification by alirocumab: insights from the ODYSSEY OUTCOMES trial.
    Diaz R; Li QH; Bhatt DL; Bittner VA; Baccara-Dinet MT; Goodman SG; Jukema JW; Kimura T; Parkhomenko A; Pordy R; Reiner Ž; Roe MT; Szarek M; Tse HF; White HD; Zahger D; Zeiher AM; Schwartz GG; Steg PG;
    Eur J Prev Cardiol; 2021 Mar; 28(1):33-43. PubMed ID: 33755145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world pharmacogenetics of statin intolerance: effects of SLCO1B1, ABCG2 , and CYP2C9 variants.
    Lönnberg KI; Tornio A; Hirvensalo P; Keskitalo J; Mustaniemi AL; Kiiski JI; Filppula AM; Niemi M
    Pharmacogenet Genomics; 2023 Sep; 33(7):153-160. PubMed ID: 37490620
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atorvastatin Metabolite Pattern in Skeletal Muscle and Blood from Patients with Coronary Heart Disease and Statin-Associated Muscle Symptoms.
    Lauritzen T; Munkhaugen J; Peersen K; Kristiansen O; Sverre E; Nebauer SD; Villseth M; Andersen AM; Svarstad AC; Jensen EP; Bergan S; Husebye E; Vethe NT
    Clin Pharmacol Ther; 2023 Apr; 113(4):887-895. PubMed ID: 36622792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of atorvastatin on muscle symptoms in coronary heart disease patients with self-perceived statin muscle side effects: a randomized, double-blinded crossover trial.
    Kristiansen O; Vethe NT; Peersen K; Wang Fagerland M; Sverre E; Prunés Jensen E; Lindberg M; Gjertsen E; Gullestad L; Perk J; Dammen T; Bergan S; Husebye E; Otterstad JE; Munkhaugen J
    Eur Heart J Cardiovasc Pharmacother; 2021 Nov; 7(6):507-516. PubMed ID: 32609361
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of High-Intensity Statins in the Veteran Population: Atorvastatin 40 to 80 mg Compared With Rosuvastatin 20 to 40 mg.
    Stein B; Ward T; Hale G; Lyver E
    Ann Pharmacother; 2020 May; 54(5):405-413. PubMed ID: 31718234
    [No Abstract]   [Full Text] [Related]  

  • 15. Statin-associated muscle symptoms in coronary patients: design of a randomized study.
    Munkhaugen J; Vethe NT; Fagerland MW; Dammen T; Perk J; Gjertsen E; Otterstad JE; Gullestad L; Bergan S; Husebye E
    Scand Cardiovasc J; 2019 Jun; 53(3):162-168. PubMed ID: 31030568
    [No Abstract]   [Full Text] [Related]  

  • 16. Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy.
    Foody JM; Toth PP; Tomassini JE; Sajjan S; Ramey DR; Neff D; Tershakovec AM; Hu H; Tunceli K
    Vasc Health Risk Manag; 2013; 9():719-27. PubMed ID: 24265554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of pharmacogenetics on statin-induced myopathy in South-Indian subjects.
    Ramakumari N; Indumathi B; Katkam SK; Kutala VK
    Indian Heart J; 2018 Dec; 70 Suppl 3(Suppl 3):S120-S125. PubMed ID: 30595243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome: Role of Lipoprotein(a) and Modification by Alirocumab: Prespecified Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial.
    Schwartz GG; Steg PG; Szarek M; Bittner VA; Diaz R; Goodman SG; Kim YU; Jukema JW; Pordy R; Roe MT; White HD; Bhatt DL;
    Circulation; 2020 May; 141(20):1608-1617. PubMed ID: 32223446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-Effectiveness of Alirocumab in Patients With Acute Coronary Syndromes: The ODYSSEY OUTCOMES Trial.
    Bhatt DL; Briggs AH; Reed SD; Annemans L; Szarek M; Bittner VA; Diaz R; Goodman SG; Harrington RA; Higuchi K; Joulain F; Jukema JW; Li QH; Mahaffey KW; Sanchez RJ; Roe MT; Lopes RD; White HD; Zeiher AM; Schwartz GG; Gabriel Steg P;
    J Am Coll Cardiol; 2020 May; 75(18):2297-2308. PubMed ID: 32381160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Alirocumab on Mortality After Acute Coronary Syndromes.
    Steg PG; Szarek M; Bhatt DL; Bittner VA; Brégeault MF; Dalby AJ; Diaz R; Edelberg JM; Goodman SG; Hanotin C; Harrington RA; Jukema JW; Lecorps G; Mahaffey KW; Moryusef A; Ostadal P; Parkhomenko A; Pordy R; Roe MT; Tricoci P; Vogel R; White HD; Zeiher AM; Schwartz GG
    Circulation; 2019 Jul; 140(2):103-112. PubMed ID: 31117810
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.